Year: 2022

TAMPA, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) — Kforce Inc. (NASDAQ: KFRC), a solutions firm that specializes in technology and other professional staffing services, will release third-quarter results post-market on Monday, October 31, 2022, followed by a conference call at 5:00 pm ET to discuss the results. The dial-in number is (888) 550-5417 and the conference passcode is “Kforce”.  The live webcast can be accessed at this link. A replay of the call will be available at http://investor.kforce.com for one year after the call. Also announced today, Kforce Inc. management will participate at the following conferences:JPMC Ultimate Services Conference in New York on November 17, 2022. Details of the Firm’s presentation time and webcast information may be accessed when available at http://investor.kforce.com. 4th Annual Truist Securities...

The non-provisional patent application seeks to protect methods and systems to automatically generate reusable microchip’s layout blocks IPs SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT” or the “Company”), filed a non-provisional patent application seeking to protect an Electronic Design Automation (EDA) software technology, internal code name Phi, which software is designed to automate the generation of reusable integrated circuits (IC) layout blocks. The concept produces a layout according to the IC’s description and its goal is to save time during the design of a microchip. The intellectual property block can be used as a black-box to be inserted within existing or future IC projects, as a plug-and-play unit, with the goal of enabling time saving by avoiding entire re-design...

FLORHAM PARK, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies, announced the promotion of two senior executives and the formation of a new Executive Committee. John R. Haines was named Senior Executive Vice President, General Manager and Chief Administrative Officer, having served previously as Chief Operating Officer. Brad Glover, Ph.D., was named Executive Vice President and Chief Operating Officer, having served previously as Executive Vice President and Chief Technical Officer. Both Mr. Haines and Dr. Glover will serve on a newly formed Executive Committee under Robert J. Hariri, M.D., Ph.D., Celularity’s Chair, Chief Executive Officer, and Founder. Mr. Haines joined our company in September 2017...

Figure 1 UAV Drone Survey Processed Results – Total Magnetic IntensityNine Mile Brook VMS Hinge Target A / Brunswick #12 Deposit (Hinge and Surface Footprint) Figure 2 – Comparison Magnetics (Nine Mile Brook VMS Target Hinge A and Brunswick #12 Deposit and Extension)Figure 3 1,000-line kms UAV drone gridVANCOUVER, British Columbia, Oct. 06, 2022 (GLOBE NEWSWIRE) — NINE MILE METALS LTD. (CSE: NINE, OTCQB: VMSXF, FSE: KQ9) (the “Company” or “Nine Mile”) announces its 1,000-line Kms UAV Magnetics Drone Survey has discovered three (3) massive VMS source targets, two (2) additional new Spruce Lake formation VMS target systems and a host of additional high priority lens targets. Nine Mile Metals has already filed for the necessary drill permits to include in our Stage 2 drill program, which is to begin in the coming...

PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present clinical and translational data from the DesCAARTes™ trial of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV) in a poster presentation at the upcoming 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), which is being held at the Edinburgh International Conference Centre in Edinburgh, Scotland from October 11-14, 2022. Details of the poster presentation are as follows: Title: Characterization of DSG3-CAART cells prior to & following adoptive transfer in mucosal Pemphigus VulgarisPoster ID Number: P370Session Title:...

NORCROSS, Ga., Oct. 06, 2022 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its second data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in patients with liver cirrhosis caused by non-alcoholic steatohepatitis (NASH). NAVIGATE is the first study of its kind and is a global effort that recruits patients in over 15 countries and five continents. The main efficacy objective is the primary prevention of esophageal varices. Patients enrolled in the study have liver cirrhosis caused by NASH and, because of the advancing cirrhotic process, have already developed portal hypertension but have not yet developed esophageal varices as a complication of portal...

Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases Development programs prioritized and organization structured to align with mitochondrial disease-focused strategy Plans to meet with FDA in Q4 2022 to discuss MELAS development program CAMBRIDGE, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced its mitochondrial disease-focused corporate strategic plan. Propelled by the positive data from the recently completed CY6463 Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) clinical study, the Company believes it has a unique opportunity to deliver the first-ever approved medicine for patients suffering from rare mitochondrial diseases, a family of debilitating,...

Project Processes Methane From California Dairy Farms Into Renewable Natural Gas for Use as Low-carbon Transportation FuelCUPERTINO, CA, Oct. 06, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Aemetis, Inc. (NASDAQ: AMTX), a renewable natural gas and renewable fuels company focused on negative carbon intensity products, announced today the closing of $25 million of long-term financing with Greater Commercial Lending (GCL), which provides loans to businesses and organizations in under-served and rural communities, to build dairy biogas digesters and a biogas pipeline for the Aemetis Biogas Central Dairy Digester Project located in Stanislaus County, California. The long-term, 20-year project financing was guaranteed by the U.S. Department of Agriculture (USDA) through the Rural Energy for America Program (REAP) and carries approximately...